Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Imel Biotherapeutics

Request full access

Cell-based therapies for mitochondrial dysfunction and targeting mitochondrial dysfunction

Waltham, United StatesFounded 2019Robotics

About Imel Biotherapeutics

IMEL BioTx is a pioneering biotech startup focused on addressing mitochondrial dysfunction, a key factor in aging and various age-related diseases such as neurodegenerative disorders, cancer, and inflammatory diseases. The company operates in the biotechnology and healthcare market, targeting both inherited and acquired mitochondrial disorders. Their primary clients include elderly patients who suffer from these conditions and healthcare providers seeking advanced treatment options.

IMEL BioTx's business model revolves around developing innovative therapies that enhance the effectiveness of cancer immunotherapies, particularly for elderly patients. The company leverages cutting-edge research and expertise in immunology to create treatments that can overcome the resistance to checkpoint inhibitors—a common issue in older cancer patients due to T cell exhaustion. By improving the immune system's ability to fight tumors, IMEL BioTx aims to provide better therapeutic outcomes for this demographic.

The company generates revenue through the development and commercialization of its proprietary therapies. This includes partnering with pharmaceutical companies for drug development, conducting clinical trials, and eventually bringing these therapies to market. Additionally, IMEL BioTx may license its technologies and collaborate with other biotech firms to expand its reach and impact.

Dr. Nicholas P. Restifo, a renowned physician and immunologist, joined IMEL BioTx as Senior Scientific Advisor in 2023. With a distinguished career that includes roles at the US National Cancer Institute and Lyell Immunopharma, Dr. Restifo brings invaluable expertise in cancer immunotherapy to the company. His involvement underscores IMEL BioTx's commitment to scientific excellence and innovation in developing new treatments.

Source: Dealroom company data

Imel Biotherapeutics in the Waltham ecosystem

Live from Dealroom

The Imel Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • CKD Venture Capital Corporation
  • Schmidt
  • WeVenture
  • Hyundai Investment Partners
  • Posco
  • L&S Venture Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Waltham HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Imel Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Imel Biotherapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.